Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 11, 2007 - Issue 11
Submit an article Journal homepage
215
Views
41
CrossRef citations to date
0
Altmetric
Review

X-linked inhibitor of apoptosis protein as a therapeutic target

Emma J Dean Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK +44 161 446 3000; +44 161 446 3977; [email protected], [email protected]; University of Manchester, Paterson Institute for Cancer Research, Wilmslow Road, Manchester M20 4BX, UK +44 161 446 3156; +44 161 446 3109
, BMedSci MB BS MRCP,
Malcolm Ranson Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK +44 161 446 3000; +44 161 446 3977; [email protected], [email protected]
, BSc(Hons) MBChB FRCP PhD,
Fiona Blackhall Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK +44 161 446 3000; +44 161 446 3977; [email protected], [email protected]
, BSc MBChB MRCP PhD &
Caroline Dive University of Manchester, Paterson Institute for Cancer Research, Wilmslow Road, Manchester M20 4BX, UK +44 161 446 3156; +44 161 446 3109
, BPharm PhD
Pages 1459-1471 | Published online: 26 Oct 2007

Bibliography

  • HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2000) 100:57-70.
  • SHEPHERD FA, RODRIGUES PEREIRA J, CIULEANU T et al.: Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. (2005) 353:123-132.
  • SANDLER AB, GRAY R, BRAHMER J et al.: Randomized Phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an eastern cooperative oncology group (ECOG) trial – E4599. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23(16S):4.
  • GIANTONIO BJ, CATALANO PJ, MEROPOL NJ: High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the eastern cooperative oncology group (EGOC) study E3200. Program and Abstracts of the American Society of Clinical Oncology 2005 Gastrointestinal Cancers Symposium. Hollywood, Florida, USA (27 – 29 January 2005):(Abstract 169a).
  • KERR JF, WYLLIE AH, CURRIE AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer (1972) 26:239-257.
  • RAFF M: Cell suicide for beginners. Nature (1998) 398(6707):119-122.
  • LEIST M, JAATTELA M: Four deaths and a funeral: from caspases to alternative mechanisms. Nat. Rev. Mol. Cell Biol. (2001) 2(8):589-598.
  • KLUCK RM, BOSSEY-WETZEL E, GREEN DR, NEWMEYER DD: The release of cytochrome C from mitochondria: a primary site for bcl-2 regulation of apoptosis. Science (1997) 275:1132-1136.
  • SALEH A, SRINIVASULA S, ACHARYA S, FISHEL R, ALNEMRI ES: Cytochrome C and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation. J. Biol. Chem. (1999) 274:17941-17945.
  • ZOU H, HENZEL WJ, LIU XLA, WANG X: Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome C-dependent activation of caspase-3. Cell (1997) 90:405-413.
  • ZOU H, LI Y, LIU X, WANG X: An APAF-1 cytochrome C mutimeric complex is a functional apoptosome that activates procaspase-9. J. Biol. Chem. (1999) 274:11549-11556.
  • SHI Y: Mechanisms of caspase activation and activation and inhibition during apoptosis. Mol. Cell (2002) 9:459-470.
  • KISCHKEL FC, HELBARDT S, BEHRMANN I et al.: Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signalling complex (DISC) with the receptor. EMBO J. (1995) 14(22):5579-5588.
  • KANG JJ, SCHABER MD, SRINIVASULA SM et al.: Cascades of mammalian caspase activation in the yeast Saccharomyces cervisiae. J. Biol. Chem. (1999) 274:3189-3198.
  • STENNICKE HR, JÜRGENSMEIER JM, SHIN HDQ et al.: Pro-caspase-3 is a major physiologic target of caspase-8. J. Biol. Chem. (1998) 273:27084-27090.
  • SALVESEN GS, DIXIT VM: Caspase activation: the induced-proximity model. Proc. Natl. Acad. Sci. USA (1999) 96:10964-10967.
  • COHEN GM: Caspases: the executioners of apoptosis. Biochem. J. (1997) 326(Part 1):1-16.
  • YIN XM: Bid, a BH3-only multi-functional molecule, is at the cross road of life and death. Gene (2006) 369:7-19.
  • CROOK NE, CLEM RJ, MILLER LK: An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J. Virol. (1993) 67:2168-2174.
  • DEVERAUX QL, TAKAHASHI R, SALVESEN GS, REED JC: X-linked IAP is a direct inhibitor of cell-death proteases. Nature (1997) 388:300-304.
  • SUN C, CAL M, GUNASEKERA AH et al.: NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP. Nature (1999) 401:818-821.
  • ROTHE M, PAN MG, HENZEL WJ, AYRES TM, GODEDDEL DV: The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell (1995) 83:1243-1252.
  • UREN AG, COULSON EJ, VAUX DL: Conservation of baculovirus inhibitor of apoptosis repeat proteins (BIRPs) in viruses, nematodes, vertebrates and yeasts. Trends Biochem. Sci. (1998) 23:159-162.
  • SALVESEN GS, DUCKETT CS: IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell Biol. (2002) 3:401-410.
  • VERHAGEN AM, COULSON EJ, VAUX DL: Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol. (2001) 2:3001-3010.
  • LI F, AMBROSINI G, CHU EY et al.: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature (1998) 396:580-584.
  • DEVERAUX QL, ROY N, STENNICKE HR et al.: IAPs block apoptotic events induced by caspase-8 and cytochrome C by direct inhibition of distinct caspases. EMBO J. (1998) 17:2215-2223.
  • TAKAHASHI R, DEVERAUX Q, TAMM I et al.: A single BIR domain of XIAP sufficient for inhibiting caspases. J. Biol. Chem. (1998) 273:7787-7790.
  • SRINIVASULA SM, HEGDE R, SALEH A et al.: A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature (2001) 410:112-116 [Erratum in Nature (2001) 2411(6841):1081].
  • DAN H, SUN M, KANEKO S et al.: Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J. Biol. Chem. (2004) 279(7):5405-5412.
  • SUZUKI Y, NAKABAYASHI Y, TAKAHASHI R: Ubiquitin–protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc. Natl. Acad. Sci. USA (2001) 98:8662-8667.
  • YANG Y, FANG S, JENSEN JP, WEISSMAN AM, ASHWELL JD: Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science (2000) 288:874-877.
  • DUCKETT CS, NAVA VE, GEDRICH RW et al.: A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. EMBO J. (1996) 15:2685-2689.
  • DEVERAUX QL, LEO E, STENNICKE HR et al.: Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J. (1999) 18:5242-5251.
  • CHEN Z, NAITO M, HORI S et al.: A human IAP-family gene, apollon, expressed in human brain cancer cells. Biochem. Biophys. Res. Commun. (1999) 264:847-854.
  • VUCIC D, STENNICKE HR, PISABARRO MT, SALVESEN GS, DIXIT VM: ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr. Biol. (2000) 10:1359-1366.
  • KASOF GM, GOMES BC: Livin, a novel inhibitor of apoptosis protein family member. J. Biol. Chem. (2001) 276:3238-3246.
  • RICHTER BWM, MIR SS, EIBEN LJ et al.: Molecular cloning of ILP-2, a novel member of the inhibitor of apoptosis protein family. Mol. Cell Biol. (2001) 21:4292-4301.
  • LISTON P, FONG WG, KORNELUK RG: The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene (2003) 22:8568-8580.
  • MAIER JK, LAHOUA Z, GENDRON NH et al.: The neuronal apoptosis inhibitory protein is a direct inhibitor of caspases 3 and 7. J. Neurosci. (2002) 15:2035-2043.
  • AMBROSINI G, ADIDA C, ALTIERI DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. (1997) 3:917-921.
  • HAUSER HP, BARDROFF M, PYROWOLAKIS G, JENTSCH S: A giant ubiquitin-conjugating enzyme related to IAP apoptosis inhibitors. J. Cell Biol. (1998) 141:1415-1422.
  • HAO Y, SEKINE K, KAWABATA A et al.: Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function. Nat. Cell Biol. (2004) 6:849-860.
  • GIANANI R, JARBOE E, ORLICKY D et al.: Expression of survivin in normal, hyperplastic and neoplastic colonic mucosa. Hum. Pathol. (2001) 32:119-125.
  • TANAKA K, IWAMOTO S, GON G et al.: Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin. Cancer Res. (2000) 6:127-134.
  • TAMM I, WANG Y, SAUSVILLE E et al.: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. (1998) 58:5315-5320.
  • CONWAY EM, POLLEFEYT S, CORNELISSEN J et al.: Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. Blood (2000) 95:1435-1442.
  • LEWIS J, BURSTEIN E, REFFEY SB et al.: Uncoupling of the signaling and caspase-inhibitory properties of X-linked inhibitor of apoptosis. J. Biol. Chem. (2004) 279:9023-9029.
  • KARIN M, LIN A: NF-κB at the crossroads of life and death. Nat. Immunol. (2002) 3:221-227.
  • CLAVERIA C, CAMINERO E, MARTINEZ AC, CAMPUZANO S, TORRES M: GH3, a novel proapoptotic domain in Drosophila Grim, promotes a mitochodrial deeath pathway. EMBO J. (2002) 21:3327-3336.
  • DU C, FANG M, LI Y, LI L, WANG X: Smac, a mitochondrial protein that promotes cytochrome C-dependent caspase activation by eliminating IAP inhibition. Cell (2000) 102:33-42.
  • VERHAGEN AM, SILKE J, EKERT PG et al.: HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins. J. Biol. Chem. (2002) 277:445-454.
  • VERHAGEN AM, EKERT PG, PAKUSCH M et al.: Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell (2000) 102:43-53.
  • HEGDE R, SRINIVASULA SM, ZHANG Z et al.: Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein–caspase interaction. J. Biol. Chem. (2002) 277:432-438.
  • SUZUKI Y, IMAI Y, NAKAYAMA HTK, TAKIO K, TAKAHASHI R: A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol. Cell (2001) 8:613-621.
  • TAMM I, KORNBLAU SM, SEGALL H et al.: Expression and prognostic significance of IAP-family genes in human cancer and myeloid leukemias. Clin. Cancer Res. (2000) 6:1796-1803.
  • TAMM I, RICHTER S, OLTERSDORF D et al.: High expression levels of X-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin. Cancer Res. (2004) 10:3737-3744.
  • RAMP U, KRIEG T, CALISKAN E et al.: XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Hum. Pathol. (2004) 35(8):1022-1028.
  • MIZUTANI Y, NAKANISHI H, LI YN et al.: Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int. J. Oncol. (2007) 30(4):919-925.
  • NAKAGAWA Y, ABE S, KURATA M et al.: IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am. J. Hematol. (2006) 81(11):824-831.
  • LI M, SONG T, YIN ZF, NA Y: XIAP as a prognostic marker of early recurrence of nonmuscular invasive bladder cancer. Chin. Med. J. (Engl.) (2007) 120(6):469-473.
  • FERREIRA CG, VAN DER VALK P, SPAN SW et al.: Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clin. Cancer Res. (2001) 7:2468-2474.
  • FERREIRA CG, VAN DER VALK P, SPAN SW et al.: Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. Ann. Oncol. (2001) 12:799-805.
  • ESPINOSA M, CANTU D, HERRERA N et al.: Inhibitors of apoptosis proteins in human cervical cancer. BMC Cancer (2006) 27(6):45.
  • WILKINSON JC, CEPERO E, BOISE LH, DUCKETT CS: Upstream regulatory role for XIAP in receptor-mediated apoptosis. Mol. Cell Biol. (2004) 24:7003-7014.
  • BEREZOVSKAYA O, SCHIMMER AD, GLINSKII AB et al.: Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res. (2005) 65:2378-2386.
  • HOLCIK M, YEH C, KORNELUK RG, CHOW T: Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increase resistance to radiation induced cell death. Oncogene (2000) 19:4174-4177.
  • LACASSE EC, BAIRD S, KORNELUK RG, MACKENZIE AE: The inhibitors of apoptosis IAPs and their emerging role in cancer. Oncogene (1998) 17:3247-3259.
  • SASAKI H, SHENG Y, KOTSUJI F, TSANG BK: Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemresistant human ovarian cancer cells. Cancer Res. (2000) 60:5659-5666.
  • CHAWLA-SARKAR M, BAE SI, REU FJ et al.: Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell (2004) 11:915-923.
  • MCMANUS DC, LEFEBVRE CA, CHERTON-HORVAT G et al.: Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene (2004) 23:8105-8117.
  • TONG QS, ZHENG LD, WANG L et al.: Downregulation of XIAP expression induces apoptosis and enhances chenotherapeutic sensitivity in human gastric cancer cells. Cancer Gene Ther. (2005) 12:509-514.
  • LI F, ACKERMANN EJ, BENNETT CF et al.: Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat. Cell Biol. (1999) 1:461-466.
  • HARLIN H, BIRKEY REFFEY S, DUCKETT CS, LINDSTEN T, THOMPSON CB: Characterization of XIAP-deficient mice. Mol. Cell Biol. (2001) 21:3604-3608.
  • CROOKE ST: Molecular mechanisms of antisense drugs: RNAaseH. Antisense Nucleic Acid Drug Dev. (1998) 8:133-134.
  • BILIM V, KASAHARA T, HARA N, TAKAHASHI K, TOMITA Y: Role of XIAP in the malignant phenotype of translational cell cancer (TCC) and therapeutic activity in XIAP antisense oligonucleotides against multidrug-resistance TCC in vitro. Int. J. Cancer (2003) 103:29-37.
  • CAO C, MU Y, HALLAHAN DE, LU B: XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene (2004) 23:7047-7052.
  • RANSON M, DIVE C, WARD T et al.: A Phase I trial of AEG35156 (XIAP antisense) administered as a continuous intravenous infusion in patients with advanced tumors. J. Clin. Oncol., ASCO Annual Meeting Proceedings Part I (2006) 24(18S):3059.
  • CHEN J, XIAO XQ, DENG CM, SU XS, LI GY: Downregulation of xIAP expression by small interfering RNA inhibits cellular viability and increases chemosensitivity to methotrexate in human hepatoma cell line HepG2. J. Chemother. (2006) 18(5):525-531.
  • ZHANG S, DING F, LUO A et al.: XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics. Cancer Biol. Ther. (2007) 6(6):[Epub ahead of print].
  • GIAGKOUSIKLIDIS S, VELLANKI SH, DEBATIN KM, FULDA S: Sensitization of pancreatic carcinoma cells for γ-irradiation-induced apoptosis by XIAP inhibition. Oncogene (2007):[Epub ahead of print].
  • MCMANUS DC, LEFEBVRE CA, CHERTON-HORVAT G et al.: Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene (2004) 23(49):8105-8117.
  • SHIOZAKI EN, CHAI J, RIGOTTI DJ et al.: Mechanism of XIAP-mediated inhibition of caspase-9. Mol. Cell (2003) 11:519-527.
  • OOST TK, SUN C, ARMSTRONG RC et al.: Discovery of potent antagonsits of the antiapoptotic protein XIAP for the treatment of cancer. J. Med. Chem. (2004) 47:4417-4426.
  • ARNT CR, CHIOREAN MV, HELDEBRANT MP, GORES GJ, KAUFMANN SH: Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J. Biol. Chem. (2002) 277:44236-44243.
  • YANG L, MASHIMA T, SATO S et al.: Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res. (2003) 63:831-837.
  • FULDA S, WICK W, WELLER M, DEBATIM KM: Smac agonists sensitize for TRAIL/Apo2L- or anticancer drug-induced apoptosis and induce regression of human glioma xenografts. Nat. Med. (2002) 8:808-815.
  • LI L, THOMAS RM, SUZUKI H et al.: A small molecule Smac mimic potentiates TRAIL- and TNFα-mediated cell death. Science (2004) 305:1471-1474.
  • SUN H, NIKOLOVSKA-COLESKA Z, LU J et al.: Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic. J. Med. Chem. (2006) 49(26):7916-7920.
  • NIKOLOVSKA-COLESKA Z, XU L, HU Z et al.: Discovery of embelin as a cell-permeable, small-molecule weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicin three-dimensional structure database. J. Med. Chem. (2004) 47:2430-2440.
  • SCHIMMER AD, WELSH K, PINILLA C et al.: Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumour activity. Cancer Cell (2004) 5:25-35.
  • WANG Z, CUDDY M, SAMUEL T et al.: Cellular, biochemical, and genetic analysis of mechanism of small molecule IAP inhibitors. J. Biol. Chem. (2004) 279:48168-48176.
  • KARIKARI CA, ROY I, TRYGGESTAD E et al.: Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Mol. Cancer Ther. (2007) 6:957-966.
  • WU TY, WAGNER KW, BURSULAYA B, SCHULTZ PG, DEVERAUX QL: Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction. Chem. Biol. (2003) 10:759-767.
  • YAGIHASHI A, ASANUMA K, NAKAMURA M et al.: Detection of anti-survivin antibody in gastrointestinal cancer patients. Clin. Chem. (2001) 47(9):1729-1731.
  • YAGIHASHI A, OHMURA T, ASANUMA K et al.: Detection of autoantibodies to survivin and livin in sera from patients with breast cancer. Clin. Chim. Acta (2005) 362(1-2).
  • ROHAYEM J, DIESTELKOETTER P, WEIGLE B et al.: Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res. (2000) 60(7):1815-1817.
  • RAMI A, AGARWAL R, SPAHN A: Synergetic effects of caspase 3 and μ-calpain in XIAP-breakdown upon focal cerebral ischemia. Neurochem. Res. (2007).
  • KEANE RW, KRAYDIEH S, LOTOCKI G et al.: Apoptotic and anti-apoptotic mechanisms following spinal cord injury. J. Neuropathol. Exp. Neurol. (2001) 60(5):422-429.
  • EBERHARDT O, COELLN R, KUGLER S et al.: Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neurosci. (2000) 20:9126-9134.
  • WAGENKNECHT B, HERMISSON M, GROSCURTH P et al.: Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome C release. J. Neurochem. (2000) 75:2288-2297.
  • LEONARD K, PETRIN D, COUPLAND S et al.: XIAP protection of photoreceptors in animal models of retinitis pigmentosa. PLoS One (2007) 2:E314.
  • COOPER L, CHAN D, ROEDIGER F et al.: AAV-mediated delivery of the caspase inhibitor XIAP protects against cisplatin ototoxicity. Otol. Neurotol. (2006) 27(4):484-490.
  • CUMMINGS J, WARD TH, LA CASSE E et al.: Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br. J. Cancer (2005) 92:532-538.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.